|本期目录/Table of Contents|

[1]游 通,黄渝茹,刘 英,等.慢性阻塞性肺疾病缓解期规律与不规律药物使用对疗效的影响分析[J].中华肺部疾病杂志,2025,(02):321-325.[doi:10.3877/cma.j.issn.1674-6902.2025.02.022]
　You Tong,Huang Yuru,Liu Ying,et al.Analysis of the effect of regular and irregular drug use in the remission period of chronic obstructive pulmonary disease[J].,2025,(02):321-325.[doi:10.3877/cma.j.issn.1674-6902.2025.02.022]
点击复制

慢性阻塞性肺疾病缓解期规律与不规律药物使用对疗效的影响分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2025年02期
页码:
321-325
栏目:
论著
出版日期:
2025-04-25

文章信息/Info

Title:
Analysis of the effect of regular and irregular drug use in the remission period of chronic obstructive pulmonary disease
作者:
游 通; 黄渝茹; 刘 英; 罗兴艳; 罗 琴
644000 宜宾,宜宾市第三人民医院呼吸科
Author(s):
You Tong;  Huang Yuru;  Liu Ying;  Luo Xingyan;  Luo Qin.
Department of respiratory medicine, the Third People's Hospital of Yibin, Yibin 644000, China
关键词:
肺疾病; 慢性阻塞性;  缓解期;  规律药物治疗
Keywords:
Chronic obstructive pulmonary diseases;  Remission period;  Regular drug therapy
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2025.02.022
摘要:
目的 观察规律与不规律药物治疗对慢性阻塞性肺疾病(chronic obstructive pulmonary, COPD)缓解期患者12个月内急性发作次数、总治疗费用、呼吸困难指数(dyspnea index, mMRC)和COPD评估测试评分(COPD evaluation test score, CAT)、第一秒最大用力呼气容量(forced expiratory capacity in the first second, FEV1)的影响。方法 选择2019年9月至2023年9月我院确诊COPD缓解期患者117例,根据用药是否规律情况,52例不规律用药为对照组,65例规律用药为观察组。观察组长期规律吸入糖皮质激素(inhalated corticosteroids, ICS)联合长效β2受体激动剂(long-acting β2-receptor agonists, LABA),如沙美特罗氟替卡松粉吸入剂(舒利迭)、布地奈德福莫特罗粉吸入剂(信必可),或长期吸入长效抗胆碱能药物(long-acting muscarine anticholinergic, LAMA),如噻托溴铵,或三联制剂,如氟替美维、布地格福等。观察两组治疗后 12个月急性加重次数、经济费用情况、mMRC和CAT评分、FEV1。结果 用药期间,观察组急性加重(主要为咳嗽、咳痰,在门诊接受治疗后缓解)次数出现1次32例、2次2例、3次1例; 对照组急性加重(主要为咳嗽、咳痰,在门诊接受治疗后缓解; 部分出现明显的呼吸困难、气短等症状,住院治疗后缓解)次数出现2次27例、3次23例、4次2例。治疗12个月后,观察组FEV1值(1.11±0.31)L、mMRC评分(1.85±0.89)分、CAT评分(14.23±5.12)分低于对照组(0.74±0.15)L,(2.81±0.73)分,(25.86±2.84)分(P<0.05); 观察组总医疗费用(7 096.25±2 731.87)元低于对照组(9 780.00±3 093.74)元(P<0.05)。 结论 COPD缓解期患者,遵从医嘱用药者,长期规律吸入药物治疗能改善患者肺功能,提高生活质量,减少住院次数,降低医疗费用。
Abstract:
Objective To observe the effects of regular and irregular medication on the frequency of acute exacerbations, total treatment costs, dyspnea index(mMRC), COPD assessment test scores(CAT), and forced expiratory volume in the first second( FEV1)over a 12-month period for patients with COPD in remission. Methods A total of 117 patients diagnosed with COPD in remission at our hospital from September 2019 to September 2023 were select. Patients were divided into a control group of 52 who used medications irregularly and an observation group of 65 who used medications regularly. The observation group received long-term regular inhaled corticosteroids(ICS)combined with long-acting β2 receptor agonists(LABA), such as salmeterol fluticasone powder inhaler(Sulair), budesonide formoterol powder inhaler(Xinafo), or long-acting anticholinergic drugs(long-acting muscarine anticholinergic, LAMA), such as tiotropium bromide, or triple formulations, such as fluticasone propionate and budesonide. Observe the number of acute exacerbations, total economic costs, mMRC and CAT scores, and FEV1 in both groups at 12 months post-treatment. Results During the medication period, the observation group experienced 1 exacerbation(mainly coughing and sputum production, relieved after outpatient treatment)in 32 cases, 2 in 2 cases, and 1 in 1 case; the control group experienced 2 exacerbations(mainly coughing and sputum production, relieved after outpatient treatment; some with significant dyspnea and shortness of breath, relieved after hospitalization)in 27 cases, 3 in 23 cases, and 4 in 2 cases. After 12 months of treatment, the FEV1 value(1.11±0.31)L, mMRC score(1.85±0.89)points, and CAT score(14.23±5.12)points in the observation group were lower than those in the control group(0.74±0.15)L,(2.81±0.73)points, and(25.86±2.84)points(P<0.05); the total medical expenses in the observation group(7 096.25±2 731.87)yuan were lower than those in the control group(9 780.00± 3 093.74)yuan(P<0.05). Conclusion For COPD patients in remission who follow medical advice and receive long-term regular inhalation therapy, improve lung function, enhance quality of life, reduce hospitalization frequency, and lower economic costs.

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2 白 莹, 马 娟, 吕 欣, 等. 慢性阻塞性肺疾病合并肺癌临床特征分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(3): 265-271.
3 GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:A systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Respir Med, 2020, 8(6): 585-596.
4 Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health[CPH]study): A national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
5 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
6 杨丽青, 高凌云, 杨凌婧, 等. 慢性阻塞性肺疾病急性加重住院病人一年内再住院危险因素分析[J]. 西南医科大学学报, 2022, 45(5): 404-408.
7 王 军, 张海龙, 春 柳, 等. 基于中国专利数据库中药复方治疗慢性阻塞性肺疾病的用药规律研究[J]. 中药新药与临床药理, 2021, 32(10): 1556-1561.
8 孔玉琴, 唐志宇, 张 密, 等. 慢性阻塞性肺疾病中西医发病机理研究概述[J]. 实用中医药杂志, 2020, 36(10): 1365.
9 Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene / measurement sets[J]. Nucleic Acids Res, 2021, 49(D1): D605.
10 郑文江, 彭紫荆, 张天鸽, 等. 喘可治注射液穴位注射治疗慢性阻塞性肺疾病稳定期的Meta分析及试验序贯分析[J]. 中药新药与临床药理, 2019, 30(6): 725-732.
11 Wang X, Gao Y, Yang Q, et al. Pingchuanning decoction attenuates airway inflammation by suppressing autophagy via phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway in rat models of asthma[J]. J Cell Biochem, 2019, 120(3): 3833.
12 樊长征, 苗 青, 樊茂蓉, 等. 慢性阻塞性肺疾病稳定期中医临床实践指南[J]. 中国中药杂志, 2020, 45(22): 5309.
13 Rabe KF, Watz H. Chronic obstructive pulmonary disease[J]. Lancet, 2017, 389(10082): 1931-1940.
14 李伟娟. 基于微信平台的延续性护理对慢阻肺患者用药依从性的影响[J]. 齐齐哈尔医学院学报, 2019, 40(4): 515-516.
15 Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease[J]. Ann Intern Med, 2020, 173(3): ITC17-ITC32.
16 席玉婕, 唐 璇, 唐仕欢, 等. 基于多靶标药效评价体系的经典方治疗慢性阻塞性肺疾病用药规律解析[J]. 中国中药杂志, 2021, 46(21): 5710-5718.
17 Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
18 Ngo C, Phan D, Vu G, et al. Inhaler technique and adherence to inhaled medications among patients with acute exacerbation of chronic obstructive pulmonary disease in Vietnam[J]. Int J Environ Res Public Health, 2019, 16(2): 185.
19 Brandsma CA, Van Den Berge M, Hackett TL, et al. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine[J]. J Pathol, 2020, 250(5): 624.
20 Yoshida M, Minagawa S, Araya J, et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis[J]. Nat Commun, 2019, 10(1): 3145.
21 王 微, 丁 霖, 陈 茜, 等. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(4): 621-624.
22 Cantor JO, Turino GM. COPD pathogenesis: finding the common in the complex[J]. Chest, 2019, 155(2): 266.
23 Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: A review[J]. JAMA, 2019, 321(8): 786-797.
24 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
25 Alawieh A, Langley EF, Tomlinson S. Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice[J]. Sci Transl Med, 2018, 10(441): eaao6459.
26 范艺龄, 苗 青, 廖 星, 等. 《慢性阻塞性肺疾病稳定期中医临床实践指南》编制说明[J]. 中国中药杂志, 2020, 45(22): 5323.
27 Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J]. Nat Commun, 2019, 10(1): 1523.
28 Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342): 2227-2242.

备注/Memo

备注/Memo:
通信作者: 黄渝茹, Email: 270948162@qq.com
更新日期/Last Update: 2025-04-25